Genesys Orthopedics Systems, L.L.C.
$837.2K 550 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Provepharm Inc.
Provepharm Inc. reported $837,332.40 across General Payments, Research, and Ownership to 117 physicians and teaching hospitals across 165 transactions.
- $837.3K Above-median payer
- All-tracks total
- 165 Above-median volume
- Transactions
- 117 Below-median reach
- Recipients
- −$102.3K
- General Payments vs PY2023
Provepharm Inc. reported $837,332.40 across all CMS Open Payments tracks (General + Research + Ownership) to 117 physicians and teaching hospitals in Program Year 2024 - ranking #660 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $41,440.82, averaging $7.2K per recipient.
How Provepharm Inc.'s $837.3K all-tracks total breaks down
Provepharm Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
19/100
Total payments
F
18/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer provepharm-inc Provepharm Inc.
$837.3K · #660/1,925 · 0.0% industry · PY2024
- TOT $837.3K
- RANK #660
- SHARE 0.0%
- TXN 165
- RCP 117
- CAT 3
- GEN $41.4K
- ΔGEN −$102.3K
- TOP1 10.9%
- PY 2024
Volume peers
Nearest volume peer: Genesys Orthopedics Systems, L.L.C. ($837.2K)
Provepharm Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Provepharm Inc.'s CMS-reported General Payments decreased by $102.3K (−71.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: PROVEPHARM INC.PY2023: PROVEPHARM INC.PY2024: Provepharm Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $143,746.06
- PY2024
- $41,440.82
What the Data Shows for Provepharm Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Provepharm Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
30 transactions worth $39.8K make "Consulting Fee" the top general-payment category in the 3-category breakdown below, 96.0% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Consulting Fee" leads Provepharm Inc.'s 3-category general-payment breakdown at $39.8K, 96.0% of the reported total.
How Provepharm Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $39.8K | 30 | 96.0% |
| Entertainment | $1.6K | 83 | 3.9% |
| Education | $26.40 | 4 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $11,463.00 (27.7%) of $41,440.82 in this company's General Payments records across 111 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Provepharm Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Shayna Showalter
$4,500.00 across 2 reported transactions
- 2
Ellen Shapiro
$1,875.00 across 1 reported transactions
- 3
Kelly Wright
$1,770.00 across 2 reported transactions
- 4
Marie Lee
$1,688.00 across 1 reported transactions
- 5
Anil Sood
$1,630.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Provepharm Inc. ranks #660 of 1,925 by total payments (top 34% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,367 of 1,838 by HHI (bottom 26% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Music City Medical Technologies, LLC : $11.8K total payments, HHI 420
- Reel Surgical, Inc. : $22.5K total payments, HHI 417
- Brainsway USA INC : $36.9K total payments, HHI 416
- Erbe USA Inc : $161.0K total payments, HHI 415
- OsteoCentric Technologies, Inc. : $303.4K total payments, HHI 412
- Integrity Implants Inc. dba Accelus : $1.6M total payments, HHI 412
- Provepharm Inc. (this company) : $41.4K total payments, HHI 411
- TriSalus Life Sciences, Inc. : $443.3K total payments, HHI 411
- Tarsus Pharmaceuticals, Inc. : $5.3M total payments, HHI 409
- Roche Diagnostics Corporation : $552.8K total payments, HHI 407
- PROCEPT BioRobotics Corporation : $1.7M total payments, HHI 405
- Cerapedics Inc. : $796.4K total payments, HHI 405
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Provepharm Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Provepharm Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Provepharm Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Vertos Medical, Inc.
$836.6K 6,652 recipients
Compare payment profiles
BIOTRONIK NRO, Inc.
$843.1K 9,395 recipients
Compare payment profiles
Spineart USA Inc
$830.2K 1,361 recipients
Compare payment profiles
Celltrion USA Inc.
$844.6K 10,231 recipients
Compare payment profiles
Trilliant Surgical LLC.
$844.6K 932 recipients
Compare payment profiles
Put this to use
Provepharm Inc. ranks #660 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Provepharm Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.